Key Highlights

  • 20.48% is the decline per published market data (October 16, 2026) for Jaguar Health (NASDAQ:JAGX), to USD 3.65 on relative volume of 0.05. The move coincides with the October 16, 2026 ex-dividend date, though the company has not linked the two.
  • 5 common shares is the conversion ratio for each Series R preferred share on November 2, 2026. Jaguar Health (NASDAQ:JAGX) declared one preferred share per common share held on October 13, paid October 15, as dilution protection during a review of strategic alternatives.
  • 1-for-15 is the reverse split that began split-adjusted trading on September 17, 2026. Published market data show a USD 7.1 million market capitalization for Jaguar Health (NASDAQ:JAGX) and diluted EPS of minus 5,482.20, a per-share figure not independently confirmed.
  • Mid-2027 is the planned New Drug Application filing for crofelemer in microvillus inclusion disease, a rare pediatric condition. Jaguar Health (NASDAQ:JAGX) presented preliminary short bowel syndrome results on October 13, 2026 and received an FDA fee waiver on September 22.

Price Action and Dividend Mechanics

Jaguar Health (NASDAQ:JAGX) announced the dividend on October 2, 2026 and confirmed on October 14 that Nasdaq set the ex-dividend date at October 16. Holders of record on October 13 received one Series R Convertible Preferred share per common share, plus one for certain warrants, paid October 15. On November 2, 2026 each preferred share converts into five common shares, capped at 19.99% ownership per holder, with excess shares held in abeyance. The company reserved up to 11,625,000 common shares. The preferred is not listed, and due bills assigned the dividend to buyers until October 16.

Liquidity and Price Reconciliation

The USD 3.65 quote implies a prior close of USD 4.59 (own arithmetic). Volume was 291,280 shares, or USD 1.06 million of turnover (own arithmetic), equal to 15.0% of the USD 7.1 million market capitalization. Relative volume of 0.05 implies an average of 5.83 million shares, which is inconsistent with a market value implying 1.95 million shares, so relative volume is not relied on. A holder of one common share holds six after conversion, so full adjustment implies an 83% lower per-share price, or USD 0.61 on USD 3.65 (own arithmetic). The measured 20.48% fall is far smaller, and the price level is not independently confirmed.

Dilution, Pipeline and Risk Review

The 1-for-15 reverse split raised the quoted price on September 17, 2026 without changing company value. The board gave no specifics on the strategic alternatives. Napo Pharmaceuticals, the subsidiary, reported preliminary crofelemer results in short bowel syndrome on October 13, but the drug is unapproved and the microvillus inclusion disease filing is mid-2027. Cash, going concern language and listing compliance are not disclosed in the filings reviewed.

Where Things Stand

Jaguar Health (NASDAQ:JAGX) fell 20.48% on the day the dividend went ex, consistent with an ex-dividend adjustment, but the company has not confirmed the link and the measured decline is far smaller than the 83% implied by full adjustment. The balance of evidence is risk-led: share count expansion on November 2, an open-ended strategic review, a USD 7.1 million market value and a pipeline without approved revenue. Next dated events: the November 2, 2026 conversion, the post-conversion share count, any strategic announcement and crofelemer filing updates.